NCT00006089View on ClinicalTrials.gov

Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

September 18, 2000

Primary Completion Date

September 4, 2007

Study Completion Date

January 31, 2010

Conditions
Endometrial AdenocarcinomaERBB2 Gene AmplificationRecurrent Uterine Corpus CarcinomaStage III Uterine Corpus Cancer AJCC v7Stage IV Uterine Corpus Cancer AJCC v7
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Trastuzumab

Given IV

Trial Locations (1)

19103

Gynecologic Oncology Group, Philadelphia

All Listed Sponsors
collaborator

Gynecologic Oncology Group

NETWORK

lead

National Cancer Institute (NCI)

NIH

NCT00006089 - Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer | Biotech Hunter | Biotech Hunter